ERYTECH Pharma S.A. (ERYP)
$0.81
+0.11 (+15.60%)
Rating:
Recommendation:
Buy
| Symbol | ERYP |
|---|---|
| Price | $0.81 |
| Beta | 2.237 |
| Volume Avg. | 0.05M |
| Market Cap | 29.586M |
| Shares () | - |
| 52 Week Range | 0.3-2.18 |
| 1y Target Est | - |
| DCF Unlevered | ERYP DCF -> | |
|---|---|---|
| DCF Levered | ERYP LDCF -> | |
| ROE | -67.94% | Strong Sell |
| ROA | -27.85% | Sell |
| Operating Margin | - | |
| Debt / Equity | 194.10% | Buy |
| P/E | -0.81 | |
| P/B | 0.95 | Buy |
Latest ERYP news
About
Download (Excel)ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.